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Improving event‑based progression 
analysis in glaucomatous visual 
fields
Chiara Rui1, Giovanni Montesano2,3*, David P. Crabb2, Paolo Brusini4, 
Balwantray C. Chauhan5, Luca M. Rossetti6, Paolo Fogagnolo6, Jean‑Marie Giraud7,8, 
Jean‑Rémi Fenolland7,8 & Francesco Oddone9
Glaucoma is a progressive optic neuropathy with characteristic changes to the optic nerve head and 
the visual field (VF). Detecting progression of VF damage with Standard Automated Perimetry (SAP) 
is of paramount importance for clinical care. One common approach to detecting progression is to 
compare each new VF test to a baseline SAP test (event analysis). This comparison is made difficult by 
the test–retest variability of SAP, which increases with the level of VF damage, and the limited range 
of measurement, meaning that damage cannot be assessed below a certain level. We performed a 
prospective international multi‑centre data collection of SAP data on 90 eyes from 90 people with 
glaucoma and different levels of VF damage over a short period of time (6 tests in 60 days). Data were 
collected using a fundus tracked perimeter (Compass, CenterVue). We used these data (minus the 
first test) to develop an improved event analysis that accounts for both the change in variability with 
damage and the lower bound on the measurement imposed by SAP. Using simulations, we show that 
our approach is more sensitive compared to previously developed methods, especially in the case of 
advanced glaucoma, while retaining similar specificity.
Glaucoma is a progressive optic neuropathy characterised by typical morphological changes to the optic nerve 
head (ONH) and the retina. Functional damage from glaucoma manifests as characteristic defects to the visual 
field (VF). Monitoring the progression of VF damage is of paramount importance for clinical management and 
is the main outcome of many glaucoma  trials1–8. The VF is usually measured with Static Automated Perimetry 
(SAP). In SAP, circular stimuli of different intensities are projected at various predetermined locations on the 
retina. Efforts have been made to improve the reliability of the exam, for example with the use of fundus track-
ing technology to compensate for eye movements (Fundus tracked Automated Perimetry, FAP). The Compass 
fundus perimeter (CMP, CenterVue, Padova, Italy) is a FAP device that includes all conventional perimetric test 
patterns employed for testing glaucoma patients, such as the 24-2 of the Humphrey Field Analyzer (HFA, Carl 
Zeiss Meditec, Dublin, CA)9.
Despite advances in perimetric hardware and software, variability remains a major hurdle in assessing VF 
progression. The CMP has proven useful, compared to HFA, in reducing test–retest variability for global  indices9, 
indicating a possible improvement from using FAP. However, measurements at individual locations retained the 
typical increased variability at lower sensitivities observed with  SAP9. Although several aspects can contribute 
to long-term variability, the systematic relationship between sensitivity and variability is thought to be a conse-
quence of the shallower psychometric  function10 in locations with lower sensitivity. As a consequence, methods 
to assess pointwise progression of VF damage need to account for such differences in variability. Event-based 
analyses are common methods to assess point-wise progression. An example is the Guided Progression Analysis 
(GPA) algorithm implemented for the HFA which seeks to identify changes in sensitivity-related metrics that 
fall outside the expected 95% test–retest limits for a specific location, based on an estimate of baseline damage. 
Because this analysis is conducted pointwise, there is an increased chance of identifying locations with change 
exceeding the test–retest limits, even in stable patients, leading to False Positives (FP). Empirical rules have been 
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implemented to curb this phenomenon, requiring a given number of locations to be outside the limits to classify 
 progression11–13. However, these empirical rules do not account for the fact that variability at more damaged 
locations is so large that the 95% lower limits would fall outside the range testable by the VF  device14. These 
locations would therefore not contribute to the False Positive Rate (FPR) and accounting for this characteristic 
could improve the detection of progression in more damaged VFs without compromising specificity.
For this study, we prospectively collected test–retest series with the CMP perimeter in a cohort of 90 stable 
glaucoma patients, stratified by VF damage. We used these data to evaluate a novel event-based approach that 
accounts for the number of locations in which progression can effectively be observed (adaptive rule) and com-
pare this to a fixed decision rule and the empirical GPA decision thresholds. Progression was simulated with 
realistic rates of VF decay from an independent cohort of glaucoma patients.
Results
Sample description. Ninety eyes of 90 subjects (55 males, 35 females) were recruited. The sample was com-
posed of 34 (37.8%) eyes with early glaucomatous loss, 28 (31.1%) eyes with moderate glaucomatous loss and 28 
(31.1%) with advanced loss. The characteristics of the study sample are summarized in Table 1. All patients had 
6 reliable VF tests but only 5 were used (the first practice test was discarded).
Test–retest variability limits. Figure 1 shows the test–retest distribution for the sensitivity, the Total Devi-
ation (TD) and the Pattern Deviation (PD) values, stratified by baseline sensitivity. The test–retest distribution 
was obtained from all 10,800 permutations of the test–retest series. Baseline sensitivity was estimated by taking 
the average of the first two VFs of each permutated series. TD and PD are values derived from sensitivity. TD 
accounts for the effect of both normal ageing and eccentricity. PD also accounts for global changes in the VF, for 
example in the case of cataract, highlighting localized VF loss. As expected, the test–retest variability increased 
at lower sensitivities with all metrics. The test–retest limits were calculated as the 5% quantile of the test–retest 
distribution for each metric at each baseline sensitivity value. A floor effect is clearly visible for sensitivity values 
with an average baseline sensitivity < 15 dB, below which value the test–retest limit exceeds the dynamic range of 
the instrument. Details of the calculations are reported in the “Methods”. We performed an additional analysis 
(reported as supplementary material) to investigate factors associated with test–retest variability, measured as 
the absolute residuals for each location in each VF with respect to the average across the five repetitions, simi-
larly to Choi et al.15. The average MD was the only significant predictor of increased variability (p = 0.014), but 
this significance was lost when stratifying by the average sensitivity of each location (p = 0.628). Changes in vari-
ability at different locations were also explored using Bland–Altman16 plots (supplementary material).
Event analysis. Point-wise linear progression of VF damage was simulated at each location similarly to Wu 
et al.17. The pointwise slopes to simulate change over time were derived from the Longitudinal Glaucoma VFs 
Table 1.  Descriptive statistics of the test–retest sample. IQR interquartile range, MD mean deviation, PSD 
pattern standard deviation, BCVA best corrected visual acuity, IOP intra ocular pressure; Early glaucomatous 
loss: − 6 dB ≤ MD ≤ 0 dB; Intermediate glaucomatous loss: − 12 dB ≤ MD < − 6 dB; Advanced glaucomatous loss: 
MD < − 12 dB.
Early loss (N = 34) Intermediate loss (N = 28) Advanced loss (N = 28)
Sex (male:female) 19:16 17:11 19:8
Age (years) 65 [58.5, 72.5] 68 [64, 73.5] 66 [60.5, 75.5]
BCVA (logMAR) 0.0 [0.0, 0.02] 0.0 [0.0, 0.10] 0.0 [0.0, 0.10]
24-2 MD (dB) − 3.5 [− 5.2, − 2.0] − 8.2 [− 10.5, − 6.1] − 13.6 [− 18.9, − 11.2]
24-2 PSD (dB) 7.2 [4.2, 8.9] 11.1 [9.8, 13.0] 12.4 [10.8, 13.2]
Figure 1.  Test–retest distribution for sensitivity (left), Total deviation (middle) and Pattern deviation (right) 
values stratified by baseline sensitivities values (average of two tests). The red lines show the lower 5% limits 
derived for each baseline sensitivity values.
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(LGVFs) database from the Rotterdam Ophthalmic data  repository18,19, a collection of 278 VF series from glau-
coma patients tested with the Full Threshold (FT) algorithm with the HFA. Each eye in our sample was matched 
to one eye in the LGVFs dataset using the average sensitivity at baseline. Details of the simulation and matching 
methodology are reported in the “Methods” and supplementary material. The average pointwise progression 
rate for the matched sample was − 0.29 ± 1.24 dB/year. Series with simulated progression were used together with 
permutations of the stable test–retest series to determine the rate of detection of progression (Hit Rate, HR) and 
the FPR of the different event-based progression methods. A progression event was identified when sensitivity 
(or TD/PD value) fell below the test–retest limits for the baseline. We combined the results of different locations 
using different rules to account for the expected FPR, according to the number of locations considered: the fixed 
rule always considered all 52 locations; the adaptive rule excluded locations affected by the floor effect, where no 
progression could be assessed. We calculated the HR and FPR obtained by combining individual events (E1), 
and two or three consecutive events (E2 and E3 respectively). These were compared with an implementation of 
the GPA. Details are provided in the “Methods” and supplementary material.
Figures 2 and 3 report the results of the event detection with the three algorithms for sensitivities, TD and PD 
as cumulative percentage of HR and FPR at each visit. The shaded bands represent the 95% quantiles around the 
central estimate from different realisations of the simulation (i.e., permutations of the template/field sequences), 
used to define the variability of the estimate.
Figure 2.  Cumulative percentage of FPR of the three progression analyses (Adaptive rule, Fixed rule and 
GPA) for sensitivity (left), Total Deviation (centre) and Pattern Deviation (right). Cumulative detection rates 
are reported for each follow-up visit (6, 12 and 18 months) and for each progression type (E1, E2 and E3). The 
horizontal dashed line indicates 5% FPR.
Figure 3.  Cumulative percentage of HR of the three progression analyses (Adaptive rule, Fixed rule and GPA), 
for sensitivities (left), Total Deviation (centre) and Pattern Deviation (on the right). Cumulative detection rates 
are reported for each follow-up visit (6, 12 and 18 months) and for each progression type (E1, E2 and E3). The 
horizontal dashed line indicates 5% HR.
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The FPR for E1 at first follow-up (6 months) was in general close to the desired 5%. However, it was on aver-
age larger when the adaptive rule was applied to the sensitivities (8.2%) and TD maps (9%) in the group with 
intermediate damage and for the PD maps for eyes with early damage (10.2% for the fixed rule and 10.7% for the 
adaptive rule). As expected, the FPR was much lower than 5% for the advanced cases with the fixed rule (0.4% 
for the sensitivities, 1.4% for TD and 0.6% for PD). However, the 5% limit was outside the 95% variability range 
of the estimate only for the PD maps in subjects with early damage and in the advanced group for the fixed rule 
with any map. Beyond the first follow-up, the FPR for E1 steadily increased, as expected. The HR was generally 
higher for the adaptive rule. Importantly, the HR for the advanced cases when the adaptive rule was applied 
to the sensitivities (7.7%) and the TD values (9.8%) was close to that obtained in the overall sample (10.6% for 
sensitivities, 11.7% for TD). The HR was instead extremely reduced for the fixed rule (1.1% for sensitivities, 2.3% 
for TD) and the GPA (0% for sensitivities, 0% for TD).
The FPR for E2 at the second follow-up (12 months) was lower or very close to 5% in all cases and was very 
similar among all detection methods. The only meaningful difference, as expected, was observed for the advanced 
cases where the FPR was higher with the adaptive rule applied to the sensitivities (1.5% for the adaptive rule, 
and 0.2% for the fixed rule and GPA) and TD values (1.9% for the adaptive rule, and 0.5% for the fixed rule and 
GPA). Concordantly, the HR was also better for the adaptive rule in advanced cases (5.6% for the sensitivities 
and 6.7% for the TD), doubled compared to the fixed rule and the GPA (3% for the sensitivities and 3.3% for 
the TD for both methods).
For E3 at the last follow-up (18 months) the fixed and adaptive rules behaved very similarly across the whole 
spectrum of damage both in terms of FPR and HR, with marginally higher FPR and HR compared to GPA.
Tables with the full numerical results are provided in the supplementary material. The average (SD) number 
of locations available for progression was 45.7 (7.9) for patients with early glaucomatous loss, 37 (9) for patients 
with intermediate glaucomatous loss and 25.5 (11) for patients with advanced glaucomatous loss.
We performed an additional analysis (reported in supplementary material) to investigate progression with a 
point-wise trend  analysis20, showing substantial equivalence between all metrics.
Discussion
We compared different algorithms to detect event-based progression. We derived our data from test–retest series 
in 90 glaucoma patients, stratified by VF damage. Our simulations relied on a method that accounts for global 
fluctuations in sensitivity across different locations in the VF, estimated from the  data17. This is particularly 
important to accurately estimate the performance of event-based analyses, which instead assume each location 
is independent.
The observed test–retest distribution for the Compass was very similar to that reported in a previous study 
with a smaller  dataset9. The variability increased substantially for sensitivities below 25 dB, in accordance with 
previous  literature14,21,22, reaching the floor for the lower 5% limits at 15 dB. Interestingly, such a value has often 
been reported as a lower bound for locations to be informative for progression  detection14,23. Indeed, some 
newly implemented testing strategies have also considered not testing locations with sensitivities below 15  dB24 
because of their limited usefulness. Our data confirm this view, showing that such locations are not informative 
for event-based progression. The test–retest variability was very similar between sensitivities, TD and PD. It is 
important to notice that, differently from the Swedish interactive thresholding algorithm (SITA) employed by 
the HFA, the CMP does not make use of any spatial smoothing or growth patterns in the testing  strategy9,25,26. 
Testing each location independently could lead to an increase in test–retest variability at lower sensitivities 
despite fundus tracking as reported in our previous  study9. However, locations below 15 dB have been shown to 
be scarcely informative for progression also with SITA  strategies14,27, implying that such differences are unlikely 
to be relevant for practical applications. Differently from previous analyses and from the traditional  GPA21, the 
expected lower 5% limits for TD and PD was modelled based on the average baseline sensitivity rather than the 
average TD or PD values. This reflects the idea that sensitivity, rather than TD or PD, is the main determinant 
of response  variability10. This is supported by our supplemental analysis showing that no other factors were 
significant predictors of increased variability when accounting for sensitivity. It is important to note, however, 
that locations with the same sensitivity have been shown to have very different variability, such as in Chauhan 
et al.28. In their analysis, however, sensitivity was still a better parameter than TD to characterise systematic 
changes in variability. This supports our choice of baseline sensitivity as the best, albeit imperfect, parameter to 
model the expected test–retest variability.
When comparing the different methods of event-based analysis, we found that they performed similarly in 
the overall sample. The GPA for E3 offered a lower HR with minor improvement in the FPR compared to the 
other methods. Compared to previous reports on the performance of the  GPA21,29–31, our analysis yielded similar 
values for the FPR and HR for “likely progression” detection (0% and 3.7% respectively in the overall sample 
with PD values). However, for “probable progression” the specificity was higher than previously reported. Artes 
et al.30 showed a cumulative FPR close to 5% at 2 and 3 cumulative tests, similar to our results. However, Wu 
et al.29 reported a FPR of approximately 8% at 2 and 3 cumulative tests. In our simulations, the FPR with the 
GPA “probable progression” never exceeded the 5% threshold, despite using a similar simulation methodology. 
Of course, several differences could have contributed to this discrepancy, including the different perimeter 
employed and the use of a tobit model to estimate and simulate progression instead of a logistic function and the 
different sample composition (see supplementary material). The use of the same dataset to define the test–retest 
limits and to test our detection strategies could have influenced the measured performance, but this effect was 
minimized by the use of a leave-one-out approach in the simulations. One novel aspect of our analysis is that we 
grouped locations based on the average baseline sensitivity to calculated the lower 5% limits for event detection. 
This is different from how variability for the PD values was handled for the  GPA21, which was instead stratified 
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according the average of baseline PD values. Our decision was taken in recognition of the fact that the major 
determinant of perimetric variability is the  sensitivity10, independently of the general height or normal ageing.
Similarly to us, Wu et al. showed that the GPA had a smaller HR for more damaged fields, but did not 
investigate the corresponding change in  specificity29. With our analysis, we show that such a reduction in the 
HR is connected to an unwanted increase in specificity at more advanced stages, derived from the static rules 
applied to detect progression. Indeed, such a feature was shared by our fixed rule detection. On the contrary, the 
adaptive rule maintained a more homogeneous FPR across the severity spectrum. This effect was absent for the 
E3 detection, which was unchanged between the fixed and adaptive rules, but resulted in important improve-
ments for the advanced cases for the E1 and E2 detections. Interestingly, for early and advanced cases, the FPR 
for E1 detection was below the 5% threshold with the fixed rule and very close to 5% for the adaptive rule in 
the advanced group. The 5% limit was also always well within the 95% variability range of the FPR estimate 
form the simulations for all classes of damage. For the advanced class, this was accompanied by an important 
increase in HR. This has clinical relevance for the advanced cases, in which faster detection of VF deterioration 
would be desirable to prevent progression to significant visual impairment or blindness. Progression with E1 
criteria had low specificity for patients with intermediate damage using sensitivity and TD values. This could 
be explained by the gradual shift towards more variable sensitivities. Importantly, except for the E1 criterion, 
both the HR and the FPR were virtually identical between the fixed and adaptive rule for intermediate and early 
patients. Moreover, both the fixed and adaptive rule generally outperformed the GPA, especially for the 3-Event 
detection, in terms of HR (higher) with minimal changes to the FPR, which remained < 5%. It must be noted 
that most of the methodology for the GPA was developed in the context of the Early Manifest Glaucoma Trial 
(EMGT)32 which was meant to detect progression in patients with early glaucomatous  damage12,32. It is therefore 
unsurprising that such a methodology would perform poorly in intermediate and advanced cases, proving often 
too conservative for clinical applications.
The performance of detection with PD was worse for all detection criteria compared to that with sensitivities 
and TD. The detrimental effect of using PD was particularly evident for patients with early damage, in which 
specificity was generally lower compared to sensitivities and TD, and in advanced cases, in which the HR was 
reduced. This is in agreement with previous reports, showing that PD based metrics might hide progression in 
glaucoma  patients14,31. One aspect to consider is that our dataset did not contain patients with visually significant 
cataract. However, the reported effect of lens opacity on the VF has been variable, ranging from  significant33–36 
to  negligible37,38, with a measured effect on global indices, such as the MD, of approximately 1 dB. Therefore, the 
role of metrics meant to account for generalised VF depression, such as the PD, remains unclear in the context 
of determining glaucoma progression, also in consideration of the potential masking effect of such  indices31 and 
their limited reliability in advanced glaucoma damage.
One limitation of our analysis is that the length of the test–retest series did not allow for permutations/simu-
lations of more than 5 visual fields per patient. Further differences between the methods might arise in longer 
series. However, this study was meant to test the performance of event-based analyses for early detection of 
progression, where they would be more clinically relevant. Moreover, longitudinal VF series collected with the 
Compass in glaucoma patients are not yet available and simulation of progression had to rely on data collected 
with an  HFA19,39. However, we based our simulations on noise estimates from the observed test–retest distribu-
tion, in an attempt to reliably mimic what would really be observed in a real-life use of the device.
In conclusion, our proposed adaptive rule has the potential to be more useful in the clinical practice than 
current implementations of the event analysis, such as the GPA, especially in patients with advanced damage. 
Sensitivities and TD values offered similar performance, but TD has the potential for wider application by 
accounting for normal ageing. Fundus-tracked perimetry might also better meet the assumption, in event-based 
analyses, that the same retinal locations are being tested at all follow-ups. However, from our previous  report9, 
this feature did not translate to a clear reduction in pointwise test–retest variability over HFA. Therefore, the 
effective clinical improvement brought by fundus tracking in detecting progression needs to be determined with 
longitudinal VF series on progressing glaucoma patients and comparing data collected with and without the use 
of fundus tracking technology.
Methods
Data collection for test–retest variability. Data were collected as part of a longitudinal open-label 
international multicentre study. Five sites took part in the study: IRCCS Fondazione “G. B. Bietti”, Rome, Italy; 
Polyclinic Città di Udine, Udine, Italy; Ophthalmology Service and Glaucoma Center HIA Begin. Paris, France; 
Eye Care Centre, Nova Scotia Health, Halifax, Canada; and ASST Santi Paolo e Carlo, Milan, Italy. Recruitment 
started on August 30, 2018 and ended on December 20, 2019. We enrolled 90 consecutive patients with glau-
coma, testing one eye per subject. The study eye was randomly selected if both eyes met the inclusion criteria. 
Eyes were stratified into three groups according to disease severity, using the 24-2 Mean Deviation (MD) of the 
most recent reliable HFA test: (1) early glaucomatous loss (− 6 dB ≤ MD ≤ 0 dB); (2) moderate glaucomatous loss 
(− 12 dB ≤ MD < − 6 dB); (3) advanced glaucomatous loss (MD < − 12 dB).
Inclusion criteria were as follows: (1) Age between 18 and 80 years; (2) Best corrected visual acuity log-
MAR ≤ + 0.1 (≥ 8/10 decimal); (3) Spherical refraction between − 12D and + 15D (limits of autofocus in the 
CMP); (4) Astigmatism between − 2D and + 2D; (5) Clinically determined glaucomatous optic nerve damage; 
(6) Abnormal optical coherence tomography (OCT) scan of the retinal nerve fibre layer (RNFL) and optic nerve 
head (ONH) in at least one sector, with reference to the normative values specific of each device used; (7) At least 
5 available reliable VF tests within the last 5 years; and (8) repeatable VF defects in the last 2 reliable VF tests, 
defined as: (i) MD or pattern standard deviation (PSD) outside 95% confidence limits (p < 0.05); (ii) Glaucoma 
Hemifield Test (GHT) outside normal limits; and (iii) A cluster of at least 3 points with p < 0.05 in the PSD map, 
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one of each with p < 0.01 affecting the same hemifield, however, the cluster could not be contiguous with the 
blind spot and could not cross the horizontal  midline40.
Exclusion criteria were as follows: (1) Any ocular surgery except uncomplicated cataract surgery and/or 
glaucoma surgery performed less than 6 months prior to data collection; (2) Any ocular pathology that could 
affect the VF other than glaucoma; (3) Use of any drug that could hinder the perimetric examination or its results; 
and (4) Angle-closure glaucoma.
Eligible patients were identified from the clinical registry of the glaucoma clinics in each recruiting centre. All 
patients gave written informed consent to participate in the study. Ethics Committee approval was obtained for 
each centre from the local ethical committee (Approval from the coordinating centre: Comitato Etico Centrale 
IRCCS Lazio, Sezione IRCCS I.F.O., June, 26, 2018, ref: N. 68 /18/FB). This study adhered to the tenets of the 
Declaration of Helsinki.
At the first visit, each subject underwent the following examinations in both eyes (besides the VF test): 
autorefraction, best corrected visual acuity, clinical assessment of the optic disc with slit lamp/ophthalmoscopy/
fundus picture, OCT of the RNFL and ONH if a recent scan (< 3 months from data collection) was not available, 
Goldman applanation tonometry and gonioscopy.
Visual field testing protocol. VF examinations were performed with the CMP using a ZEST (Zippy Esti-
mation through Sequential Testing)25,41 strategy and a 24-2+ grid. The 24-2+ grid has the same 52 locations of 
the standard 24-2 grid (excluding the two blind spot locations) with 12 additional points in the macular region 
(Fig. 4). If the patient was eligible, a first test (Practice) and 5 additional retests were performed within a period 
of about 1 month (average 31 days, range [16–44] days) with a mean interval of 6 days (range [1–15] days) 
between tests. All tests were considered reliable if the rate of false positive errors was ≤ 18%, the rate of false 
negative errors was ≤ 30% and the average pupil diameter during each test was > 2.8 mm (the threshold to ensure 
reliable imaging and tracking with the CMP). The tests were performed in follow-up mode, so that the same 
retinal locations were tested in each examination.
The Practice test was not included in the analysis and served to familiarise the patient with the testing 
procedure.
Simulation of progressing fields. Simulations were performed using the method proposed by Wu et al.17 
to obtain longitudinal visual field series. The details are reported in the supplementary material. Briefly, the 
method uses noise templates to simulate variability in the VFs while maintaining correlations across locations 
within the same test. This is an important factor in VF variability, sometimes referred to as the Global Visit 
 Effect42, since the fluctuations in sensitivity at different visits are not independent across different locations. The 
method also accounts for the larger variability at lower sensitivity values and derives the noise distributions from 
the empirical test–retest data to specifically simulate the noise observed in CMP from this data collection. The 
pointwise slopes for sensitivity change over time were derived from the LGVFs  database18,19, a collection of 278 
VF series from glaucoma patients tested with the Full Threshold (FT) algorithm with the HFA. Both FT and the 
ZEST procedure of CMP derive sensitivity at test locations independently and without reference to neighbour-
ing points. The pointwise slopes were calculated through tobit  regression39 in R (R Foundation for statistical 
computing, Vienna, Austria) using the AER  package43 to account for the floor effect at lower sensitivities (see 
supplementary material).
From the LGVFs, we selected 90 subjects matched with the participants of our test–retest dataset according 
to their baseline Mean Sensitivity (MS). For the CMP test–retest series, the MS was calculated as the mean of 
the 52 sensitivity values from the 24-2 locations, each estimated as the average value across all the VFs in the 
Figure 4.  Comparison between standard 24-2 and 24-2+ grid.
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test–retest series from the same eye. For the LGVFs, the MS was the mean of the 52 values predicted by the tobit 
regression at baseline (first visit). The pointwise slopes from the matched LGVFs subjects were used to simulate 
progression in the eyes from our test–retest dataset. For our simulations, each VF in the original test–retest series 
was transformed into a noise template (see supplementary material). We simulated all possible combinations of 
noise templates (i.e. VFs) for each eye, for a total of 10,800 simulated VFs series (120 per eye). This allowed us to 
retain the VF fluctuations actually observed in each real test–retest series. Essentially, the simulated progressing 
VF series replicated the permutations of the test–retest series, with the additional effect of the simulated decay in 
sensitivity. We simulated two baseline visits at 0 and 6 months, and then three more VF at 12, 18 and 24 months 
(total of 5 VFs, corresponding to the 5 noise templates per eye).
Event analysis. An event analysis method was developed to detect significant progression events. Based 
on the method proposed by Heijl et al.21, we used the average of two VFs in the test–retest series to define the 
baseline sensitivity for each location in each eye. The lower 5% limits for the test–retest distribution were calcu-
lated for each baseline sensitivity and used to detect significant progression events. The same calculations were 
repeated using the TD and the PD values, as provided by the CMP using an internal normative  database9. Of 
note, when calculating the 5% limits, TD and PD values were grouped according to their average baseline sensi-
tivity instead of the average TD and PD baseline values. This choice was preferred since sensitivity is known to be 
the main determinant of response variability in  perimetry10. The limits were calculated for each eye by excluding 
all data from that same eye, to avoid inflating the performance (leave-one-out). Additional details are provided 
in the supplementary material.
We compared different criteria to define a VF series as progressed. Progression could be identified by 1 event 
(E1) or two (E2) or three (E3) consecutive events at the same location. A set of fixed decision rules were used to 
combine these events at multiple locations:
• E1 progression: one event is observed in at least 6 locations
• E2 progression: two consecutive events are observed in at least 3 locations
• E3 progression: three consecutive events are observed in at least 2 locations
Similar to the GPA, the fixed rule is meant to account for the rate of expected false positives in the detection 
of the events, considering each location (N = 52) as a separate statistical test with a 5% probability of false posi-
tive error. The probability of detecting at least one false event was assumed to follow a binomial distribution (see 
supplementary material for details). However, the fixed rule does not account for locations where detecting an 
event is impossible (locations with sensitivity at Baseline below 15 dB), because the lowest 5% quantile of the 
test–retest distribution coincides with the lower measurement limit (0 dB). These locations do not contribute 
Figure 5.  Example of event analysis for an eye with advanced damage with simulated progression. The 
grayscale plots shows the visual field at baseline (average of the first two tests) and at the three follow-ups (6, 
12 and 18 months). For each follow-up test the event analysis is reported at the bottom. Empty, half-filled and 
filled triangles indicate, respectively, one, two and three consecutive events at the same location. An event is 
defined as significant deterioration beyond the 5th percentile of sensitivity test–retest limits. The crosses indicate 
locations where detection of an event is not possible. GPA detected an E2 progression (“possible progression”) at 
18 months; the Fixed rule detected an E3 progression at 18 months; the Adaptive rule detected an E2 progression 
at 12 months and an E3 progression at 18 months (first detection 6 months earlier).
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to the overall false positive rate and are more frequent in eyes with advanced damage, because lower sensitivi-
ties have larger test–retest variability (Fig. 5). We therefore proposed a modification of this rule (the second 
algorithm in our comparison, called adaptive rule) where the minimum number of locations with an observed 
event required to detect progression is adjusted according to the effective number of locations in which progres-
sion can be measured (potentially less than 52). Details are reported in the supplementary material. Finally, we 
compared our results with the empirical rules reported for  GPA11–13: no VF progression is based on E1; E2 and 
E3 progression is assessed in both cases if two (“possible progression”) or three (“likely progression”) consecu-
tive events respectively are observed in at least 3 locations. This differs from our fixed E3 criterion, where only 
2 locations are required.
We applied these algorithms to all permutations of test–retest series, assumed stable, to evaluate the FPR 
and to all simulated progressing series to measure the rate of detection (Hit Rate, HR). For each series, the first 
two tests were used as baselines for the event analysis, over a total of 5 tests. Therefore, E1 progression could be 
detected for test 3 to 5, E2 for tests 4 and 5 and E3 only for test 5. We considered 5% as the ideal benchmark for 
FPR for clinical use. The variability of our estimates is reported using the 5–95% quantiles of the results obtained 
from different realisations of our simulations (i.e., each permutation of the VF series).
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